Baboons undergoing orthotopic concordant cardiac xenotransplantation surviving more than 300 days: Effect of immunosuppressive regimen  by Asano, Miki et al.
Surgery for
Congenital
Heart Disease
Baboons undergoing orthotopic concordant cardiac
xenotransplantation surviving more than 300 days:
Effect of immunosuppressive regimen
Miki Asano, MD,a Steven R. Gundry, MD,a Hironori Izutani, MD,a Sandra Nehlsen Cannarella, PhD,b
Omar Fagoaga, PhD,b and Leonard L. Bailey, MDa
Dr Asano
Objective: We reviewed long-term survival among hosts in 3 consecutive series of
a rhesus monkey–baboon orthotopic cardiac xenotransplantation model with refer-
ence to host immune response, including the effectiveness in preventing rejection
and limiting toxicity concerning infection, to evaluate specific immunosuppressive
regimens for long-term outcomes.
Methods: Six juvenile baboons surviving more than 300 days after transplantation
were reviewed. Regimen A consisted of splenectomy, FK506, methotrexate, and
antilymphocyte globulin. Regimen B consisted of pretransplantation and chronic
maintenance with cyclosporine A (INN: ciclosporin), methotrexate, and antithymo-
cyte globulin. Regimen C was the same as regimen B plus pretransplantation total
lymphoid irradiation and intraoperative donor bone marrow cell infusion. Rejections
were detected by means of echocardiography.
Results: Long-term survivors in 3 groups were followed for a range of 332 to 515
days (mean, 436 days). Rejection frequency in regimens A, B, and C was 0.35, 0.58,
and 0.18 per month, and rescue therapy days were 23 (4.8%), 123 (9.5%), and 20
(2.4%), respectively (P  .0001). Infection frequency was 0.58, 0.56, and 0.19 per
month, and therapy days were 192 (38.2%), 164 (12.6%), and 7 (0.9%), respectively
(P  .0001). Concerning the host immune response, interleukin 2–activated T cells
of all groups during rejection-free periods showed lower numbers compared with
those of control animals (P .0005), and regimen C was the lowest among 3 groups
(P .01). The production of xenoantibody was sufficiently attenuated in all groups.
Conclusion: Regimen C leads to long-term survival with fewer rejection and
infection episodes by means of suppression of the interleukin 2 pathway and
xenoantibody production.
We have continued to study orthotopic concordant and discor-dant cardiac xenotransplantation for a solution to the severeshortage of allogeneic donor supply, especially in the fieldof cardiac transplantation in infants and children.1-10 Insteadof exploring transgenic donors, simplified host immunosup-pressive protocols that could be used in clinical cardiac
transplantation have been adapted to our xenotransplantation research. We have
focused on survival studies of orthotopically xenografted juvenile baboon recipients
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with hearts from rhesus monkey donors and successfully
obtained long-term survival outcomes in 3 consecutive se-
ries,2,7,10 using somewhat different immunosuppressive
strategies in each. We reviewed findings related to those
hosts who survived more than 300 days after transplantation
as to the effectiveness in preventing rejection and limiting
toxicity with regard to infection and the host immune re-
sponse to assess which combination of specific immunosup-
pressive regimens leads to the best long-term outcome.
Materials and Methods
Donors, Recipients, and Immunosuppressive Regimens
Eighteen juvenile baboons (body weight, 2.5-4.8 kg; age, 7-19
months) from the same colonies received orthotopic cardiac trans-
plantation from ABH blood-type compatible and mixed lympho-
cyte culture–matched rhesus monkeys. Animals were divided into
3 consecutive series on the basis of the immunosuppressive strat-
egy. Seven baboons received immunosuppressive regimen A, 6
received regimen B, and 5 received regimen C (see below). Six
recipients (1 of regimen A, 3 of regimen B, and 2 of regimen C)
survived more than 300 days after surgical intervention and were
reviewed. Regimen A consisted of preoperative splenectomy, in-
traoperative donor heart irradiation (100 cGy), administration of
antibaboon lymphocyte sheep globulin (4 mg kg1 d1) from
day 3 to day 5, FK506 (18 mg  kg1  d1), and metho-
trexate (0.1-5 mg twice weekly, dose adjusted to keep white blood
cell counts 3000) administered as maintenance immunosuppres-
sants. In regimen B 8 days of pretransplantation and peritransplan-
tation treatment with cyclosporine (INN: ciclosporin; 15 mg 
kg1 d1), methotrexate (1 mg/kg), and antithymocyte globulin
(15 mg  kg1  d1) was given. Maintenance therapy consisted
of cyclosporine (15 mg  kg1  d1) and methotrexate (0.5-5
mg twice weekly). In regimen C nonlethal total lymphoid irradi-
ation (TLI) was used in a dose of 80 cGy from a cobalt 60 source
twice weekly for 5 weeks before transplantation plus infusion of
3  108/kg bone marrow cells collected from the donor immedi-
ately after completion of surgical procedures. From 2 weeks before
transplantation, cyclosporine (15 mg  kg1  d1) and metho-
trexate (1 mg/kg twice weekly) were administered. Antithymocyte
globulin (15 mg kg1 d1) was administered from day3 to
day 10. Maintenance therapy was the same as that of regimen B.
Rescue therapy consisted of a 4-day course of methylprednisolone
(250 mg/d, Table 1).
Operative Procedures
The transplantation procedure was the same as we have described
elsewhere.11,12 In brief, xenografts were harvested from rhesus
monkeys and preserved with cold Roe crystalloid cardioplegia and
immersed in cold saline solution (4°C). In regimen A grafts were
irradiated with 100 cGy before implantation. In regimen C both
femurs and iliac crest marrow of the donor rhesus monkeys were
harvested for bone marrow transfusion. All recipients received 125
mg of methylprednisolone, antibiotic, and 3 mg/kg heparin just
before the operation. A median sternotomy was used for both
explantation and implantation of grafts. Grafts were implanted
orthotopically by using circulatory arrest. All animals were sepa-
rated from cardiopulmonary bypass without inotropic support.
Animals were extubated within 2 to 3 hours after the operation. All
recipients recovered smoothly, and no technical failure occurred.
Evaluation, Diagnosis, and Definitions
The effects of immunosuppressive regimens in long-term surviv-
ing animals were evaluated on the basis of the following: effec-
tiveness in preventing rejection and limiting toxicity with regard to
infection, cardiac function, drug dosage, physical development and
host immune response elucidated by examination of lymphocyte
subsets, and presence of xenoantibody. Rejection episodes were
evaluated by means of both rejection frequency and total rescue
therapy days. Diagnosis of rejection was mainly based on echo-
cardiography, with findings of increasing graft wall thickness, new
pericardial effusion, and deterioration of wall motion and also
based on general symptoms (ie, lethargy, anorexia, and tachycar-
dia). However, no rejection episode was diagnosed solely on the
basis of general symptoms. Echocardiography has been used clin-
ically for primary rejection surveillance after infant heart trans-
plantation at Loma Linda University Medical Center,13 and this
could be greatly valuable in these juvenile animal models with
limited venous access instead of using sequential myocardial bi-
opsies. Biopsy was used once in 2 regimen A animals, respec-
tively, to attempt to differentiate cellular versus humoral rejection.
Completion of the rejection episode was defined as that time when
rescue therapy was completed and cardiac findings were improved.
The rejection period was defined as the period from 6 days before
TABLE 1. Immunosuppressive regimens of the 3 groups (regimens A, B and C)
Pretransplantation
Pretransplantation
and
peritransplantation During transplantation Posttransplantation
Splenectomy TLI Adjunct DHI DBMI FK CsA MTX
Rescue
MP
A I ALG I I I I
B CsA,MTX ATG I I I
C I CsA,MTX ATG I I I I
DHI, Donor heart irradiation (100 cGy); DBMI, donor bone marrow infusion (3  108/kg); FK, FK506 (18 mgkg1d1); CsA, cyclosporine A (pretreatment,
15 mg.kg.d; maintenance target dose, 200300 ng/ml); ALG, antilymphocyte globulin, (4 mgkg1d1); ATG, antithymocyte globulin (15 mgkg1d1); MTX,
methotrexate (pretreatment, 1 mgkgd; maintenance dose, 0.15 mg/day); MP, methylepredonisone (4-day course rescue therapy, 250 mg /day).
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the diagnosis until the day of diagnosis because echocardiography
was used once a week routinely. The rejection-free period was
defined as the time more than 2 weeks after transplantation and at
least 2 weeks from any documented rejection episode. If infection
occurred during the rejection-free period, it was subtracted from
the rejection-free period.
Infection episodes were evaluated on the basis of both infection
frequency and total intravenous antibiotic therapy days. Diagnosis
of infection was based on the following: temperature increase to
greater than 39°C, white blood cell count of greater than 12,000,
results of blood culture, chest radiography, and clinical symptoms
(ie, diarrhea and rhinorrhea). The infection period was defined as
the duration from the day of diagnosis until the completion of
intravenous antibiotic, ganciclovir therapy, or both coupled with
improvement in findings and symptoms. The diagnosis of cyto-
megalovirus disease was made if the virus was detected in culture
from blood, sputum, or both (cytomegalovirus viremia, pneumo-
nia, or both).
Cardiac function was evaluated on the basis of left ventricular
ejection fraction. The weekly dosage of methotrexate was used as
the measure of drug dosage. The evaluation of physical develop-
ment depended on the body weight expressed as z values obtained
by transforming the observed weight in kilograms to the number of
SDs from the mean normal value by the weight obtained from
untreated baboons in our laboratory.
Peripheral blood lymphocytes and serum were collected once
or twice a week. Lymphocytes were analyzed for cell-surface
antigens (CD2, CD20, CD2CD4, CD2CD8, and
CD25CD2) by means of 2-color flow cytometry with murine
antihuman monoclonal antibodies. Xenoantibody titers against
rhesus monkey red blood cells were measured in the standard
hemagglutination assay.
Data from recipient baboons before any pretransplantation
treatment were considered control data. Concerning the immuno-
logic profiles of control animals, no difference existed among the
3 groups. According to the definition of rejection-free period and
rejection period, the number of rejection-free period versus rejec-
tion period measurement points from which data were obtained for
evaluation of each group was 31 versus 14 in regimen A, 41 versus
25 in regimen B, and 58 versus 12 in regimen C, respectively. The
number of control values was 20.
This research was approved by the institutional animal care
committee of Loma Linda University Medical Center. All animals
received human care in compliance with the Guide for the Care
and Use of Laboratory Animals prepared by the Institute of Lab-
oratory Animal Resources and published by the National Institutes
of Health (publication no. 86-23, revised 1985).
Statistical Analysis
Unless otherwise stated, continuous variables are expressed as
means  SD. Nominal variables were compared among the 3
groups by using the 2 test for independence. Continuous variables
were compared by using analysis of variance. An unpaired Student
t test was used to compare continuous variables between the
rejection-free period and the rejection period within each group.
One-way analysis of variance and post hoc testing (Scheffe
method) were used to compare the control group and the 3 groups
in the rejection-free period and to compare among the 3 groups in
the rejection period, as well as among the 3 groups when including
all animals. Actuarial survival curves obtained with the Kaplan-
Meier method were compared by using log-rank analysis. All
statistical analyses were performed with StatView 5.0 for Macin-
tosh (SAS Institute Inc).
TABLE 2. Profile of all animals among the 3 groups
Animal no.
Survival
(d) Time course of rejections (postoperative day)
Rejection
(n)
Infection
(n) Cause of death
Regimen A 1(#1) 502 55, 379, 392, 414, 420, 483 6 10 CMV pneumonia
2 234 60, 94, 188, 212, 219 5 3 Toxoplasmosis
3 123 49, 82, 90 3 5 CMV pneumonia
4 96 42 1 4 Renal failure
5 74 16, 42, 74 3 5 Pulmonary embolism
6 43 0 2 CMV pneumonia
7 35 32 1 1 Klebsiella pneumonia
Regimen B 1(#2) 515 11, 109, 395, 411, 441, 485 6 9 PTCAD
2(#3) 413 9, 25, 79, 138, 203, 216, 236, 249, 264, 287, 294 11 7 Herpes virus infection
3(#4) 371 8, 37, 141, 159, 177, 198, 269 8 4 Papova virus infection
4 223 8, 17, 28, 36, 47, 62, 84, 94, 105, 119, 127, 138, 171, 222 14 3 Acute rejection
5 59 7, 55 2 1 Acute rejection
6 50 44, 50 2 1 Acute rejection
Regimen C 1(#5) 486 20, 107, 292 3 2 Alive
2(#6) 332 135, 284 2 3 Alive
3 88 67, 85 2 0 Acute rejection
4 35 30 1 0 Acute rejection
5 10 0 0 Gastroenterocolitis
No important differences were observed among the 3 groups in the survival period. Regimen C animals showed the lowest value both in rejection frequency
(0.38  0.37/mo) and infection frequency (0.08  0.12/mo). The numbers parenthesized mean serial numbers of long-term surviving animals. CMV,
Cytomegalovirus; PTCAD, posttransplant coronary artery disease.
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Results
Profile of All Animals in the 3 Groups
Table 2 delineates the profile of all animals in the 3 groups.
The survival period of each group was 158  165 days in
regimen A, 272  193 days in regimen B, and 190  209
days in regimen C, respectively. No statistical differences
were observed among the 3 groups. Actuarial survival of the
3 groups also indicated no remarkable difference by means
of log-rank test (P  .688, Figure 1). Concerning rejection
episodes, numbers were 0.59  0.40 per month of rejection
frequency in regimen A, 0.98  0.53 per month in regimen
B, and 0.38  0.37 per month in regimen C, respectively.
There was an important difference only between regimens B
and C (P .0395). Initial rejection after transplantation was
observed on day 42.8 15.9 in regimen A, day 14.5 14.5
in regimen B, and day 63.0  52.0 in regimen C, respec-
tively. A statistical difference was obtained between regi-
mens B and C (P  .02). As regards infection episodes,
numbers were 1.10 0.55 per month of infection frequency
in regimen A, 0.48  0.10 per month in regimen B, and
0.08  0.12 per month in regimen C, respectively. Between
regimens A and C, a remarkable difference (P .0002) was
observed. Regimen C animals showed the lowest value in
infection frequency, as well as the lowest value in rejection
frequency. Importantly, infection caused 71% of the deaths
in regimen A, 33% in regimen B, and none in regimen C. In
regimen C animals 3 had grade 2 graft-versus-host disease
and died of acute rejection 88 days after transplantation.
Animal 5 died of gastroenterocolitis caused by radiation
injury. Moreover, long-term survivors had completely sim-
ilar tendencies in results concerning rejection and infection
observed among the 3 groups including all animals.
Profile of Long-term Survivors
Animal 1 in regimen A died from cytomegalovirus pneu-
monia and bacterial sepsis. Autopsy revealed severe post-
transplantation coronary arteriopathy without acute rejec-
tion. Animal 2 in regimen B died of posttransplantation
coronary arteriopathy. Another 2 animals in regimen B died
of viral infection, and no significant transplantation-related
coronary artery disease was identified (Table 2).
Rejections and Infections in Long-term Survivors
The total number of rejection episodes was 6 in regimen A
animals in 17 months, 25 (6 in animal 2, 11 in animal 3, and
8 in animal 4) in regimen B animals in 43 months, and 5 (3
in animal 5 and 2 in animal 6) in regimen C animals in 27
months, respectively. Therefore rejection frequency was
0.35 per month in regimen A animals, 0.58 per month in
regimen B animals, and 0.18 per month in regimen C
animals, respectively. The number of rescue therapy days
was 23 (4.8%) of 502 days in regimen A animals, 123
(9.5%) of 1299 days in regimen B animals, and 20 (2.4%)
of 818 days in regimen C animals, respectively. Animal 3 in
regimen B received TLI (80 cGy twice weekly; total, 800
cGy) for intractable and recurrent rejection from day 390.
Regimen C recipients were had lower values in terms of
rejection frequency and also statistically lower values in
terms of rescue therapy days (P  .0001, Table 3).
The total number of infection episodes was 10 in regi-
men A animals, 21 (9 for animal 2, 7 for animal 3, and 8 for
animal 4) in regimen B animals, and 5 (3 for animal 5 and
2 for animal 6) in regimen C animals, respectively. There-
fore infection frequency was 0.58 per month in regimen A
animals, 0.56 per month in regimen B animals, and 0.19 per
month in regimen C animals, respectively. The number of
intravenous antibiotic therapy days was 192 (38.2%) in
regimen A animals, 164 (12.6%) in regimen B animals, and
7 (0.9%) in regimen C animals, respectively. Animal 1
received ganciclovir therapy for cytomegalovirus from day
309 to day 353 and had Klebsiella pneumonia on day 334.
Animals 3 and 4 also received ganciclovir therapy from day
Figure 1. Actuarial survival of the 3 groups. Actuarial survival at 300 days after transplantation was 14.3% in
regimen A animals, 50% in regimen B animals, and 40% in regimen C animals.
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270 and day 353, respectively. Animal 2 had pneumonia
from day 412. On the contrary, regimen C animals showed
no severe infections requiring sequential intravenous anti-
biotic therapy and experienced less infection. Thus the
immunosuppressive modality used in regimen C recipients
yields fewer infection episodes (P  .0001, Table 4).
Weekly Dosage of Methotrexate in Long-term
Survivors
The dosage of methotrexate (in milligrams per week) was
3.1  2.2 in regimen A animals, 5.1  1.6 in regimen B
animals, and 4.3  1.2 in regimen C animals, respectively.
There were differences among the 3 groups (P  .0001),
with the regimen A dose being lower.
Change of Ejection Fraction in Long-term Survivors
Ejection fraction of the 3 groups in rejection-free period
versus rejection period was 77.7%  5.2% versus 72.2% 
7.5% in regimen A animals, 78.4% 4.3% versus 73.5%
5.0% in regimen B animals, and 81.1%  7.2% versus
75.3%  8.5% in regimen C animals, respectively. The
control value was 83.4%  5.9%. Although there were no
important differences among the 3 groups, regimen A and B
animals in rejection-free periods showed lower values com-
pared with control values (P  .0344 and .0187, respec-
tively; Figure 2).
Change of Body Weight
All but one (animal 3) long-term surviving animals in
regimen B increased in body weight naturally, and their z
values decreased between 0.5 and 2 up to 400 days after
transplantation. Animal 3 experienced chronic malnutrition
and frequent episodes of severe diarrhea induced by immu-
nosuppression and required tube feeding from day 90 to day
160, with whole-blood transfusions required several times
(Figure 3).
Flow Cytometric CD2 Cell Profile
The absolute number of CD2 T cells (1000 per microliter)
in the rejection-free period versus the rejection period was
2.87  1.19 versus 4.17  1.17 in regimen A animals,
1.08  0.42 versus 1.57  0.56 in regimen B animals, and
0.83  0.52 versus 2.03  0.70 in regimen C animals,
respectively. The control value was 2.87  1.22. CD2 T
cells increased during rejection periods in all groups. During
rejection-free periods, the absolute number of CD2 cells
among regimen B and C animals were lower than those of
control animals (P  .0001). During rejection periods,
CD2 cell counts were lower for regimen B and C animals
than for regimen A animals (P  .0001). Administration of
FK506 resulted in an increase of the CD2 T-cell popula-
tion, negating the difference between control and regimen A
animals (P  .9999).3,4
Flow Cytometric CD20 B-cell Profile
The absolute number of CD20 B cells (1000 per microli-
ter) in the rejection-free period versus the rejection period
was 0.21  0.19 versus 0.28  0.14 in regimen A animals,
0.22  0.07 versus 0.40  0.36 in regimen B animals, and
0.28  0.20 versus 0.47  0.20 in regimen C animals,
respectively. The control value was 0.51  0.23. In rejec-
tion-free periods, CD20 decreased in all groups compared
with that seen in the control animals (P  .0001), but no
important differences existed among the 3 groups (P 
.9973 for regimens A vs B, P  .3371 for regimens A vs C,
and P  .3807 for regimens B vs C).
Flow Cytometric CD2CD4 Helper T-cell Profile
The absolute number of CD2CD4 helper T cells (1000
per microliter) in the rejection-free period versus the rejec-
tion period was 0.89  0.50 versus 1.06  0.35 in regimen
A animals, 0.59  0.20 versus 0.81  0.30 in regimen B
animals, and 0.28  0.15 versus 0.70  0.29 in regimen C
animals, respectively. The control value was 1.54  0.66.
During rejection-free periods, CD2CD4 helper T cells
decreased in all groups compared with control values (P 
.0001), and differences existed among the 3 groups (P 
.0071 for regimens A vs B, P  .0001 for regimens A vs C,
and P  .0008 for regimens B vs C). CD2CD4 cell
TABLE 3. Rejection episodes among the 3 groups
Regimen A Regimen B Regimen C P value
Rejection
frequency
0.35 0.58 0.18
Therapy days 23 123 20 .0001(4.8%) (9.5%) (2.4%)
The total number of rejection episodes was 6 during 17 months in regimen
A, 25 during 43 months in regimen B, and 5 during 27 months in regimen C.
Regimen C recipients were lower in frequency and also lower in rescue
therapy days, with clinical significance (P  .0001).
Rejection frequency, total rejection episodes/total follow-up months; % in
parenthesis, total rescue therapy days/total follow-up days.
TABLE 4. Infection episodes among the 3 groups
Regimen A Regimen B Regimen C P value
Infection
frequency
0.58 0.56 0.19
Therapy days 192 164 7 .0001(38.2%) (12.6%) (0.9%)
The total number of infection episodes was 10 in regimen A, 21 in regimen
B, and 5 in regimen C, respectively. Therapy days means the number of
intravenous antibiotic therapy days. Regimen C recipients experienced
lower frequency and also less therapy days, with clinical significance.
Infection frequency, Total infection episodes/total follow-up months; % in
parenthesis, therapy days/total follow-up days.
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counts were the lowest for regimen C animals during rejec-
tion-free periods (Figure 4, A).
Flow Cytometric CD2CD8 Cytotoxic/Suppressor
T-cell Profile
The number of CD2CD8 cytotoxic/suppressor T cells
(1000 per microliter) in the rejection-free period versus the
rejection period was 1.69  0.81 versus 2.68  0.71 in
regimen A animals, 0.48  0.23 versus 0.73  0.31 in
regimen B animals, and 0.49  0.37 versus 1.15  0.72 in
regimen C animals, respectively. The control value was
1.31  0.62. During rejection-free periods, the number of
CD2CD8 cells decreased in regimen B and C animals
compared with control values and were also lower than
those observed in regimen A animals (P  .0001).
Flow Cytometric CD25CD2 Interleukin 2–activated
T-Cell Profile
The number of CD25CD2 interleukin 2 (IL-2)–activated
T cells (1000 per microliter) in the rejection-free period
versus the rejection period was 0.12  0.06 versus 0.15 
0.05 in regimen A animals, 0.14  0.05 versus 0.17  0.05
in regimen B animals, and 0.03  0.01 versus 0.08  0.03
in regimen C animals, respectively. The control value was
0.27  0.28. During rejection-free periods, all 3 groups
showed lower numbers compared with control values (P 
.0001 for regimens A and C, P  .0002 for regimen B), and
regimen C was the lowest among the 3 groups. Regimen C
animals were more suppressed than the other groups with
regard to IL-2–activated T cells (Figure 4, B).
Figure 2. Change in ejection fraction. Although there were no important differences among the 3 groups, regimen
A and B animals showed lower values compared with those of control animals (P  .0344 and .0187, respectively).
*Existence of difference between periods (P  .0061 for regimen A animals, P < .0001 for regimen B animals, and
P  .0167 for regimen C animals).
Figure 3. Change in body weight. All but one of the study animals increased in body weight naturally. The normal
values for 94% of the animals lies between –2 and 2 (z value  [Observed data – Mean of normal group]/SD).
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Xenoantibody in Long-term Survivors
Serum xenoantibody to donor rhesus monkey red blood
cells was not detected during the first 3 months after trans-
plantation in regimen B animals, and titers detected there-
after were low, ranging from 1:1 to 1:8. The examination of
explanted graft by means of immunohistochemistry eluci-
dated no deposits of IgG and IgM in animals 2 and 3; this
was not used in animal 4. No xenoantibody was detected in
regimen C animals, even after 1 year of transplantation.
Xenoantibody to donor lymphocyte was measured in regi-
men A animals, but no significant titers were found, and
these were equivalent to antibaboon lymphocyte antibody
titers. In addition, immunofluorescent study of the explanted
heart of animal 1 showed no deposits of IgG or IgM on the
endothelium of the coronary arteries and the aorta.6
Discussion
These 3 consecutive series of a rhesus monkey–baboon
orthotopic cardiac xenotransplantation model were con-
ducted during a nearly 10-year period at our laboratory to
refine and develop a simple and effective immunosuppres-
sive regimen that would be feasible for clinical use. During
this time, we have tried to develop a regimen that would
produce donor-specific unresponsiveness or tolerance with-
out the need for continuous immunosuppression. This was
obviously not achieved. However, comparison of the long-
term survivors indicate an obvious advantage in using reg-
imen C for xenotransplantation.
Rejection Episodes and Infection Episodes
In regimen A animals, although rejection episodes were
sufficiently controlled with FK506 and a remarkably low
Figure 4. A, CD2CD4 T cells decreased in all groups compared with control values (P < . 0001), and differences
existed among the 3 groups (P .0071 between regimens A and B and P .0008 between regimens B and C). *P
.2523 in regimen A, P  .0006 in regimen B, and P < .0001 in regimen C between both periods. B, CD25CD2
IL-2–activated T-cell profile. During rejection-free periods, all groups showed lower numbers compared with
control values (P < .0001 in regimens A and C and P  .0002 in regimen B). Regimen C was the lowest among the
3 groups in rejection-free periods (P  .0088 between regimens A and C, P < .0001 between regimens B and C).
*P  .0587 for regimen A, P  .0073 for regimen B, and P < .0001 for regimen C between both periods.
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dose of methotrexate, refractory infection episodes required
intravenous drug therapy for up to 38% of total survival
days and resulted in frequent sepsis. From the immune
profile, it appears that this regimen dose not result in ag-
gressive immunosuppression when compared with the other
2 regimens. A synergy between FK506 and methotrexate is
presumably responsible for the control of rejection. High
susceptibility to infection was possibly induced by splenec-
tomy, which does have the adverse effect of increasing late
infectious mortality.14 Although splenectomy conferred
long-term graft survival when using reduced-dose FK506,15
it reduces circulating IgM and complement levels,16,17 and
alveolar macrophage bactericidal function is depressed after
splenectomy.18 Another explanation is that FK506 predis-
poses the recipient to more serious infection and resultant
death.19
In regimen B the greater rejection frequency and greater
number of rescue therapy days was possibly induced by a
weaker suppression of the IL-2 T-cell activation pathway
than in the other 2 groups of animals (as described in the
“Host Immune Response” section). The higher dose of
methotrexate also contributed to increased susceptibility to
infection, perhaps through the reduction of antibody-form-
ing cells both after antigenic and mitogenic stimulation.20
The lowest number of rejection episodes and days of
rejection treatment and also the lowest number of infection
episodes and days of antibiotic intravenous therapy were
observed among the long-term survivors of regimen C. We
intended to produce mixed lymphohematopoietic chimerism
among recipients in regimen C. However, animal 5 showed
0.5% mixed chimerism in groin lymph node analysis by
means of flow cytometry 8 months after transplantation, and
no chimerism was detected in animal 6.10 Although TLI in
conjunction with cytolytic therapy and bone marrow trans-
fusion might render recipients a high incidence of donor-
specific tolerance through the establishment of a chimeric
status, we could not detect sufficient mixed chimerism in
this study. The construction of xenogenic chimerism is
undoubtedly difficult, but more specific reagents that can
distinguish donor hematopoietic elements from those of
recipients might be needed to say for certain that mixed
chimerism did not exist in these animals.21 Indeed, we could
not detect any evidence of chimerism in peripheral blood
lymphocytes or organ specimens of even the animals that
had graft-versus-host disease. Conversely, in an allograft
model a small fraction of donor lymphohematopoietic ele-
ments, even transiently with flow cytometry, might be suf-
ficient to designate donor-specific tolerance. Therefore the
lessened rejection and infection episodes in regimen C
animals was assumed to be the result of a stable and well-
suppressed T-cell function. The maintenance of all classes
of serum immunoglobulin in the normal range by TLI plays
an important role for protecting against infections.22 How-
ever, care must be taken for radiation gastroenterocolitis and
graft-versus-host disease in this regimen.
Ejection Fraction
Ejection fraction was maintained without any inotropic
drugs, diuretic drugs, or both in regimen C recipients. Se-
vere rejections, frequent rejections, or both preclude a com-
plete recovery of cardiac function, even after completion of
rescue therapy. Indeed, persistent paradoxical septal wall
motion, arrhythmia, and hypertrophic changes were ob-
served in several cases of non–regimen C animals. Exten-
sive replacement-type myocardial fibrosis reflecting some
prior myocardial injury was confirmed pathologically, even
without evidence of active rejection in animal 3. Animal 1
was administered digitalis and diuretics for control of a
chronic pericardial effusion from day 400 onward, and
animal 2 was prescribed diuretics and prednisone (5 mg 3
times week) from day 456 onward for chronic pericardial
effusion and peripheral edema.
Physical Development
All but one of the long-term surviving animals gained
weight, normally indicating that cardiac function was main-
tained sufficiently for physical development in almost all
animals. However, after day 400, animals 1 and 2, who
gained weight normally until approximately 5.5 to 6.2 kg,
showed cessation of body weight gain and eventually de-
creased in weight. This plateau level was almost the same as
the normal body weight of adult rhesus monkeys. It is
conceivable that hearts might be genetically programmed
for each species, and this could regulate the growth devel-
opment and maximum size of xenografts.8 However, it is
more likely that the plateau was reached simply because of
diminishing cardiac function caused by repeated rejection
episodes.
Host Immune Response
Our previous studies have suggested that both cellular and
humoral factors are responsible for the rhesus monkey–
baboon xenograft rejection,3,4,7 and therefore it is obvious
that sufficient suppression of both factors should be a req-
uisite for good long-term outcome. In general, all 3 regi-
mens suppressed T-cell function on the basis of modulated
cell numbers. CD2CD4 helper T cells and CD25CD2
IL-2–activated T cells were sufficiently decreased. In the 3
regimens, FK506 and cyclosporine, as maintenance immu-
nosuppressants, inhibit IL-2 mRNA accumulation and in-
terfere with an early step in T-cell activation by decreasing
IL-2 secretion, resulting in a decreased number of IL-2–
activated T cells23 and thus affecting T-cell proliferation. In
spite of using FK506, which is 10 to 100 times more potent
than cyclosporine in its ability to inhibit transcription of the
IL2 gene in regimen A animals, the lowest number of
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IL-2–activated T cells was observed in regimen C animals.
In regimen C animals the presence of the lowest number of
helper T cells and IL-2–activated T cells supports the pre-
vailing effect of TLI in reducing the activation of T cells by
IL-2 because it is known that helper T cells decrease per-
sistently after TLI coupled with a concomitant slow increase
in suppressor T cells, resulting in an inversion of CD4/CD8
ratio. Although this phenomenon remains incompletely de-
fined, in part the effect might be due to physiologic differ-
ences in the radiosensitivity of T cell.24,25 This predomi-
nance of suppressor T cells inhibits the generation of
cytotoxic T cells and decreases the production of cytokines
from helper T cells, including IL-2, and this reduction is a
mechanism by which TLI might induce tolerance. The host
and graft interaction was suppressed or tolerated because of
a prevalence of suppressor T cells and their ability to
attenuate helper-inducer T cells, cytotoxic T cells, and B-
cell expansion, activation, and maturation.24 This host im-
mune response profile continues to be observed over 300
days after the procedure and suggests that TLI results in a
very long-lasting immunosuppressive effect. Of course, this
effect might also be a synergistic effect of TLI and cyclo-
sporine in xenotransplantation by inhibiting xenoantibody
and cell-mediated response, especially suppressing CD4
helper T cells, thus resulting in long-term acceptance of
rhesus monkey cardiac xenografts.22,26,27
Regarding the CD20 B-cell profile and the sufficiently
attenuated xenoantibody production, all 3 regimens were
effective in suppression of B-cell function. FK506 has bi-
phasic effects on B-cell function; namely, when used at a
low dose, negative proliferation signaling through IgM is
inhibited, and an acceleration of cell division is observed.
Conversely, when administered at high doses, positive pro-
liferation signaling through IgD is suppressed, and it also
suppresses the production of tumor necrosis factor, which
acts as an autocrine growth factor for B cells.28,29 Therefore
splenectomy as a supplement to FK506 is useful to maintain
the steady suppression of B-cell numbers and function.
However, considering the increased risk of susceptibility to
infection, another specific suppression with anti–B-cell an-
tibody substituted for splenectomy should be considered. In
regimen B animals, beginning 6 months after transplanta-
tion, xenoantibody was detected but showed no relation to
rejection. It might be because the prevention of antidonor
antibody formation in the initial posttransplantation period
allowed for prolonged concordant xenograft survival.30 In
regimen C animals not surviving in the long term, very low
levels of xenoantibody titers ranging from 1:1 to 1:2 were
show, as well as and a lack of deposition of immunoglobulin
in endothelium, as determined by means of immunofluores-
cent study. However, one of these animal had acute and
chronic coronary arteriopathy in explanted grafts. Humoral
rejection is possibly one of the causes of graft coronary
arteriopathy in xenotransplantation. Differentiation between
humoral and cellular rejection is not readily possible with-
out the biopsy material in every rejection episode. Therefore
we might address the limitation of the model in that the
diagnosis of rejection episodes are not completely specific.
Conclusions
We conclude that regimen C leads to long-term survival
with fewer rejection and infection episodes. This was ac-
complished by suppression of T-cell numbers and function,
especially by inhibiting the proliferation through the IL-2
pathway, and by suppression of xenoantibody production.
Although obvious immune tolerance and chimerism were
not established, TLI resulted in a host immune response that
was readily controlled by a clinically applicable regimen of
maintenance immunosuppression that did not increase the
risk of infection.
At the time of this report, animal 5 in regimen C is still
alive on day 680, without signs of rejection and infection.
Her immune profile dose not differ from that described in
this article.
We greatly appreciate the technical support of Geoffery Visbal.
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Discussion
Dr Robert E. Michler (Columbus, Ohio). The Loma Linda group
is certainly to be congratulated for their excellent work in demon-
strating that hearts transplanted in the orthotopic position between
the monkey and baboon can survive for over 1 year. Those of us
familiar with this model recognize how difficult it is to manage
these animals, diagnose rejection, and administer medications.
Consistent 1-year orthotopic graft survival is certainly an achieve-
ment.
These results, although encouraging, were achieved with an
aggressive immunosuppressive regimen that would be difficult to
readily apply to the newborn human or young child. It is also
difficult to truly compare the effect of the 3 immunosuppressive
regimens when the data presented are limited to those recipients
who survived beyond the 300-day time point. This situation might
be analogous to comparing human immunosuppressive treatment
options by looking only at recipients of human allografts who
survived beyond an arbitrary time point, say, 5 years. Arguably,
there is something special about long-term survivors that cannot be
explained by the drug therapy alone.
This animal model is more difficult to manage than the human
recipient model. Specifically, diagnosis of rejection requires that
the animal be sedated to perform an echocardiogram, drug admin-
istration is often problematic, and symptoms cannot be easily
ascertained. Because this study was conducted over a 10-year time
frame, how certain can we be that the diagnosis and treatment of
both rejection and infection were sufficiently uniform to draw such
strong conclusions?
The Loma Linda group has continued to scientifically explore
transplantation between closely related species, and we must pre-
sume that this has been done with a particular clinical objective in
mind. It would be interesting to hear comments from the authors
on their overall strategy for human clinical application of xeno-
transplantation. The baboon remains a difficult donor choice for
humans from the perspective of availability and potential retroviral
transmission to the human recipient. It is likely that imported wild
baboons will not be acceptable to the Food and Drug Administra-
tion and the Centers for Disease Control and Prevention. Therefore
baboons bred in captivity under specific conditions will be re-
quired at considerable expense. How do the authors view the
likelihood of clinical application and its widespread effect? We
recognize and admire the experience of the Loma Linda group in
the field of xenotransplantation, as well as in newborn clinical
allotransplantation, and therefore they are uniquely qualified to
comment and advise us on this issue. Do they believe that the
newborn, for example, represents a unique immunologic situation?
Moreover, what is their perspective on the pig as a donor animal?
It is possible that public opinion and the concern for transmis-
sion of primate endogenous retroviruses will prevent the use of
nonhuman primates as donors for human subjects. Nevertheless,
the experience gained from studies such as this one reinforces the
complexities involved in transplanting organs between species. It
is expected that these same limitations will be experienced by
investigators attempting to achieve long-term survival of cardiac
xenografts between transgenic pigs and nonhuman primates, and
there is much that they can learn from the experience of the Loma
Linda group.
Every animal model has its limitations, and the need to proceed
to the clinical arena with novel therapies must take into consider-
ation the limitations imposed by the particular animal model.
Dr Gundry. If I might be so bold as to respond to these
comments for my colleague. Thank you, Dr Michler, for those very
pertinent comments, and I think we really agree with most of what
you said.
First of all, you brought up that there is a problem looking at
only the long-term survivors of all these groups. Obviously, this
has been a very long-term project at our institution, extending over
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10 years. And in each case, as we have attempted to refine the
immunosuppressive regimen, and we have tried to center on an
immunosuppressive regimen that is quite tolerable in a clinical
atmosphere. We believe that by looking at the quality of life of the
long-term survivors in this report, the regimen C animals, that is,
those receiving TLI with bone marrow infusion coupled with
pretransplantation treatment with methotrexate and cyclosporin,
seem to have a good quality of life, that is, a very low incidence of
rejection and a very low incidence of infection.
We have previously reported on all the surviving groups in
previous articles, but it was the purpose of this article to look at
what made the long-term survivors, if at all, different among the 3
groups, so that even though we attain significant long-term sur-
vival in regimen A animals, for instance, this came at a cost of
multiple episodes of infectious disease treatments and problems
probably bought on by the splenectomy. Therefore looking at the
long-term costs, we again are looking for a clinically applicable
model.
Believe it or not, our diagnosis and treatment of both rejection
and infection has not changed in our laboratory over the last 10
years. We have always based this on transesophageal echocardi-
ography on the basis of an interpretation of that echocardiogram,
as Dr Asano showed you. And the same with the treatment. We
have always used an antiviral regimen for the treatment of most of
the problems, and I can tell you that most of the problems are of
a viral nature. The unique thing about regimen C is that we did not
see that viral infection problem in the regimen C animals.
We do tend to disagree with Dr Michler about the availability
of baboons. Baboons are a ubiquitous species that are viewed as a
trash animal in Africa. They reproduce rapidly and easily. The
question of retrovirus is well taken. The Centers for Disease
Control and Prevention, working with the National Institutes of
Health, is looking at Baby Fae’s serum, even as we speak, to
decide and determine whether there is a presence of any retrovi-
ruses in her serum; the results are not available as yet. We are
looking forward to those results. Certainly any sort of primate-to-
human transplantation is going to depend on as much information
as we can obtain about retroviruses from primates to humans or
from baboons to humans.
We do, of course, continue to believe that the newborn is a
unique substrate for transplantation, and our now 11-year data
continue to bear that out. Newborns are a privileged host.
Last, as you know, we do have experience with unmodified
pigs in an orthotopic transplantation model, and we have had
survival—consistent survival—up to about 28 days in an ortho-
topic model with unmodified pigs by using much the same regimen
that you have seen here. The problem, we think, with most of the
genetic modifications of pigs is that it has only scratched the
surface, and with each passing day we are going to see more and
more of a vascular rejection rather than the hyperacute rejection.
The hyperacute rejection can be easily fixed.
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